Roth Affirms Cytori Therapeutics (CYTX) at 'Buy'; BARDA Affirms Strong Support for Thermal Burn Cell Therapy
Tweet Send to a Friend
Roth Capital affirms Cytori Therapeutics (Nasdaq; CYTX) at Buy with a price target of $3.50 following news that it and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
